Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients

Nephrology Dialysis Transplantation

Volumn 16, Issue 5, 2001, Pages 999-1008

  Stein, Günter ^c   Franke, Sybille ^c   Mahiout, Arezki ^c   Schneider, Sabine ^a   Sperschneider, Heide ^c   Borst, Sabine ^b   Vienken, Jörg ^b  

^a Kuratorium F Dialyse N   (Germany)

^b FRESENIUS MEDICAL CARE   (Germany)

^c Department of Internal Medicine IV ^*

Author keywords

Advanced glycation end products; Haemodialysis; High flux polysulfone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA 2 MICROGLOBULIN; CELLULOSE; ERYTHROPOIETIN; HEPARIN; PENTOSIDINE; POLYCARBONATE; POLYSULFONE;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; DIALYSIS MEMBRANE; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUIPMENT; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; MALE; PRECURSOR; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 0035025293     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.5.999     Document Type: Article

References (31)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-151
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234
3. Vlassara H. Protein glycation in the kidney: role in diabetes and aging. Kidney Int 1996; 49: 1795-1804
4. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28: 419-426
5. Colaco CALS, Ledesma MD, Harrington CR, Avila J. The role of the Maillard reaction in other pathologies: Alzheimer's disease. Nephrol Dial Transplant 1996; 11 [Suppl. 5]: 7-12
6. Thornalley PJ. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998; 44: 1013-1023
7. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999; 55: 389-399
8. Dolhofer-Bliesener R, Lechner B, Deppisch R et al. Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995; 10: 657-664
9. Yanagisawa K, Makita Z, Shiroshita K et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients. Metabolism 1998; 47: 1348-1353
10. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation end products. Kinetics of formation and clearence in peritoneal dialysis. J Clin Invest 1996; 97: 728-735
11. Miyata T, Ueda Y, Shinzato T et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198-1206
12. Miyata T, Ueda Y, Yoshida A et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997; 51: 880-887
13. Nakayama H, Taneda S, Kuwajima S et al. Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989; 162: 740-745
14. ε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996; 35: 8075-8083
15. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14: 328-326
16. Niwa T, Miyasaki S, Katsuzaki T et al. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 1995; 48: 771-778
17. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497
18. 2-microglobulin concentration after cuprophane haemodialysis. Lancet 1987; 1(8533): 628-629
19. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842
20. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-1522
21. Kriedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995; 25: 445-451
22. ε (carboxymethyl) lysine is increased in uremia. Kidney Int 1997; 52: 1064-1067
23. Portero-Otin M, Pamplona R, Bellmunt MJ, Bergua M, Prat J. Glycaemic control and in vivo non-oxidative Maillard reaction: urinary excretion of pyrraline in diabetes patients. Eur J Clin Invest. 1997; 27: 767-773
24. Monnier VM, Nagaraj RH, Portero-Otin M et al. Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant 1996; 11 (Suppl. 5): 20-26
25. 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187-194
26. Van Ypersele de Strihou C. Are biocompatible membranes superior for hemodialysis therapy? Kidney Int 1997; 52 [Suppl. 62]: 101-104
27. Weiss MF. Pathogenic role of advanced glycation end-products (AGEs): an overview. Perit Dial Int 1999; 19 [Suppl. 2]: 47-52
28. Jadoul M, Ueda Y, Yasuda Y et al. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of 'carbonyl stress'. Nephrol Dial Transplant 1999; 55: 2487-2492
29. Stein G, Franke S, Sperschneider H et al. Decrease in serum pentosidine levels of ESRD patients during polysulfone hemodialysis. Nephrol Dial Transplant 1999; 14: 1607-1608
30. Henle T, Deppisch R, Beck W, Hergesell O, Hänsch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968-1975
31. Stein G, Günther K, Sperschneider H et al. Clinical evaluation of a new dialyzer, FLX-12 GW, with polyester-polymer alloy membrane. Artif Organs 1993; 17: 339-345